New drug targets and small molecules for promoting cardiac regeneration

Description of the granted funding

Currently, there is no effective drug treatment for post-infarction heart failure, which is a major public health issue and a huge economic burden. The adult human heart cannot repair the tissue injury caused by myocardial infarction, and the loss of cardiomyocytes leads to the development of heart failure. Remarkably, zebrafish and neonatal rodents can regenerate their hearts. This involves generation of new blood vessels and proliferation of existing cardiomyocytes, but the mechanisms regulating these phenomena are not fully understood. By elucidating endogenous mechanisms of cardiac regeneration, this work aims to identify new drug targets for cardiac regeneration-inducing therapies and develop small molecule compounds with potential cardiac regeneration-enhancing activity.
Show more

Starting year

2019

End year

2024

Granted funding

Virpi Talman Orcid -palvelun logo
438 874 €

Related funding decisions

353109
Research costs of Academy Research Fellows(2022)
200 000 €
328909
Research costs of Academy Research Fellows(2019)
300 000 €

Funder

Research Council of Finland

Funding instrument

Academy research fellows

Other information

Funding decision number

321564

Fields of science

Pharmacy

Research fields

Farmasia

Identified topics

cardiovascular diseases